Cytek Biosciences, Inc.
Every calculator, already run for CTKB
Open the full toolkit →You have the numbers on CTKB. Get the argument.
A written report on which of these readings actually decide the outcome for Cytek Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering CTKBOwnership & short interest
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kit…
CTKB — frequently asked
Is CTKB a buy right now?
Wall Street's consensus rating on Cytek Biosciences, Inc. is Buy across 4 analysts, with a mean price target of $5.69 (+36% vs. the current $4.18). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CTKB overvalued?
CTKB trades at — trailing earnings, against a DCF fair value of $1 per share. The current price implies 27% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
Compare Cytek Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Cytek Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CTKB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Cytek Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.